269 related articles for article (PubMed ID: 26902621)
1. Indications for Augmentation Cystoplasty in the Era of OnabotulinumtoxinA.
Shreck E; Gioia K; Lucioni A
Curr Urol Rep; 2016 Apr; 17(4):27. PubMed ID: 26902621
[TBL] [Abstract][Full Text] [Related]
2. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
3. Intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity incontinence: do we need urodynamic investigation for outcome assessment?
Koschorke M; Leitner L; Sadri H; Knüpfer SC; Mehnert U; Kessler TM
BJU Int; 2017 Dec; 120(6):848-854. PubMed ID: 28771936
[TBL] [Abstract][Full Text] [Related]
4. Onabotulinum toxin A: a therapeutic option for refractory neurogenic detrusor overactivity and idiopathic overactive bladder.
Ellsworth P; Travis M
Urol Nurs; 2014; 34(4):165-71. PubMed ID: 25233617
[TBL] [Abstract][Full Text] [Related]
5. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
6. Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children.
Kim SJ; Nang QG; RoyChoudhury A; Kern AJM; Sheth K; Jacobs M; Poppas DP; Akhavan A
J Pediatr Urol; 2022 Jun; 18(3):314-319. PubMed ID: 35216926
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
[TBL] [Abstract][Full Text] [Related]
8. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
Nitti V; Haag-Molkenteller C; Kennelly M; Chancellor M; Jenkins B; Schurch B
Medicine (Baltimore); 2023 Jul; 102(S1):e32377. PubMed ID: 37499088
[TBL] [Abstract][Full Text] [Related]
9. Less is more-A pilot study evaluating one to three intradetrusor sites for injection of OnabotulinumtoxinA for neurogenic and idiopathic detrusor overactivity.
Avallone MA; Sack BS; El-Arabi A; Guralnick ML; O'Connor RC
Neurourol Urodyn; 2017 Apr; 36(4):1104-1107. PubMed ID: 27283922
[TBL] [Abstract][Full Text] [Related]
10. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity.
Sussman D; Patel V; Del Popolo G; Lam W; Globe D; Pommerville P
Neurourol Urodyn; 2013 Mar; 32(3):242-9. PubMed ID: 22965657
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of onabotulinumtoxinA in patients with previous failed augmentation cystoplasty: Cohort series and literature review.
Toia B; Pakzad MH; Hamid R; Wood DN; Greenwell TJ; Ockrim JL
Neurourol Urodyn; 2020 Aug; 39(6):1831-1836. PubMed ID: 32572987
[TBL] [Abstract][Full Text] [Related]
12. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
Rovner E; Dmochowski R; Chapple C; Thompson C; Lam W; Haag-Molkenteller C
Neurourol Urodyn; 2013 Nov; 32(8):1109-15. PubMed ID: 23389824
[TBL] [Abstract][Full Text] [Related]
13. Use of botulinum toxin for genitourinary conditions: What is the evidence?
da Silva CM; Chancellor MB; Smith CP; Cruz F
Toxicon; 2015 Dec; 107(Pt A):141-7. PubMed ID: 26235907
[TBL] [Abstract][Full Text] [Related]
14. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory neurogenic detrusor overactivity in children.
Kim SJ; Nang Q; RoyChoudhury A; Kern A; Sheth K; Jacobs M; Poppas D; Akhavan A
J Pediatr Urol; 2022 Jun; 18(3):321-322. PubMed ID: 35305930
[No Abstract] [Full Text] [Related]
16. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
[TBL] [Abstract][Full Text] [Related]
17. Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO).
Nambiar A; Lucas M
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S21-5. PubMed ID: 25042139
[TBL] [Abstract][Full Text] [Related]
18. Comment on: "Cost comparison of intra-detrusor injection of botulinum toxin versus augmentation cystoplasty for refractory Neurogenic Detrusor Overactivity in Children".
Olsen LH; Djurhuus JC
J Pediatr Urol; 2022 Jun; 18(3):323-324. PubMed ID: 35370093
[No Abstract] [Full Text] [Related]
19. Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity.
Padmanabhan P; Scarpero HM; Milam DF; Dmochowski RR; Penson DF
World J Urol; 2011 Feb; 29(1):51-7. PubMed ID: 21110030
[TBL] [Abstract][Full Text] [Related]
20. Intradetrusor botox injection and augmentation cystoplasty trends among spina bifida patients at US freestanding children's hospitals.
Vasdev R; Softness K; Cahill D; Panagides J; Logvinenko T; Saunders R; Bauer S; Estrada C; Wang HS
J Pediatr Urol; 2024 Jun; 20(3):482.e1-482.e6. PubMed ID: 38402080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
